ACTSI Investigator Dr. Christopher Flowers in the News

Christopher R. Flowers, MD, ACTSI investigator, associate professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, and director, Emory Lymphoma Program, Winship Cancer Institute

Science Daily | New Drug Shows Promise in Treating Indolent Non-Hodgkin Lymphomas
January 22, 2014

Flowers is PI on the trial PCI-32765DBL3001: A Randomized, Double-blind, Placebo-controlled Phase III Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

US News & World Report | Columbus Dispatch | Englemed Health News | Live Sicence | Science CodexCentral Valley Business Times | Daily Rx | Innovations ReportMapping a link between blood cancer, industrial pollutant in Georgia
July 29, 2013

Medical News Today | African Americans with blood cancer do not live as long as caucasians, despite equal care
July 8, 2013

Herald| CLL diagnosis and treatment update
August 23, 2012

Upcoming Events

    View All Events

    Latest News


    ACTSI-supported OculoStaple Wins Again

    Atlanta Clinical & Translational Science Institute (ACTSI)-supported team, OculoStaple wins second place in the 2015 InVenture Prize at Georgia Tech. Team members Jackie Borinski, Mohamad Ali Najia, and Drew Padilla, all biomedical...


    Infographic: What are the Phases of Clinical Trials?